TKTL1 and neoplasm: As both the targeted knockdown of TKTL1 expression as well as the compound-mediated inhibition of transketolase activity exerts strong inhibition of tumour growth, TKTL1 represents an excellent candidate for a targeted treatment of aggressive carcinomas.